These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9803831)

  • 21. Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancer.
    Geisler J; Haarstad H; Gundersen S; Raabe N; Kvinnsland S; Lønning PE
    J Endocrinol; 1995 Aug; 146(2):359-63. PubMed ID: 7561649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
    Fisher B; Jeong JH; Bryant J; Anderson S; Dignam J; Fisher ER; Wolmark N;
    Lancet; 2004 Sep 4-10; 364(9437):858-68. PubMed ID: 15351193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are breast tumours resistant to tamoxifen also resistant to pure antioestrogens?
    Wakeling AE
    J Steroid Biochem Mol Biol; 1993 Dec; 47(1-6):107-14. PubMed ID: 8274423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response to toremifene (Fc-1157a) therapy in tamoxifen failed patients with breast cancer. Preliminary communication.
    Ebbs SR; Roberts J; Baum M
    J Steroid Biochem; 1990 Jun; 36(3):239. PubMed ID: 2142244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro.
    Murphy CS; Langan-Fahey SM; McCague R; Jordan VC
    Mol Pharmacol; 1990 Nov; 38(5):737-43. PubMed ID: 2233701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alternative mechanism of action of "anti-oestrogens" in breast cancer.
    Ebbs SR; Roberts JV; Baum M
    Lancet; 1987 Sep; 2(8559):621. PubMed ID: 2887899
    [No Abstract]   [Full Text] [Related]  

  • 27. cDNA transfection followed by the isolation of a MCF-7 breast cell line resistant to tamoxifen in vitro and in vivo.
    Toi M; Harris AL; Bicknell R
    Br J Cancer; 1993 Dec; 68(6):1088-96. PubMed ID: 8260359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Antiestrogens].
    Saez S
    Presse Med; 1984 May; 13(20):1261-5. PubMed ID: 6232584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs.
    Yang G; Nowsheen S; Aziz K; Georgakilas AG
    Pharmacol Ther; 2013 Sep; 139(3):392-404. PubMed ID: 23711794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The significance of estrogen receptors in tamoxifen and toremifene therapy.
    Valavaara R; Kangas L
    Ann Clin Res; 1988; 20(5):380-8. PubMed ID: 2975479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
    Jordan VC; Brodie AM
    Steroids; 2007 Jan; 72(1):7-25. PubMed ID: 17169390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    Howell A; Howell SJ; Clarke R; Anderson E
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships.
    Allen KE; Clark ER; Jordan VC
    Br J Pharmacol; 1980; 71(1):83-91. PubMed ID: 7470748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathways to tamoxifen resistance.
    Riggins RB; Schrecengost RS; Guerrero MS; Bouton AH
    Cancer Lett; 2007 Oct; 256(1):1-24. PubMed ID: 17475399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen.
    Balkenende EM; Dahhan T; Linn SC; Jager NG; Beijnen JH; Goddijn M
    Hum Reprod; 2013 Apr; 28(4):953-9. PubMed ID: 23335608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effects and mechanism of action of antiestrogens in breast cancer].
    Borgna JL; Rochefort H
    Sem Hop; 1984 Mar; 60(10):703-9. PubMed ID: 6322320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fundamental research leading to improved endocrine therapy for breast cancer.
    Miller WR
    J Steroid Biochem; 1987; 27(1-3):477-85. PubMed ID: 3320538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
    Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
    Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-steroidal antioestrogens--receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells.
    Wakeling AE; Valcaccia B; Newboult E; Green LR
    J Steroid Biochem; 1984 Jan; 20(1):111-20. PubMed ID: 6538611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response.
    van Agthoven T; Sieuwerts AM; Meijer D; Meijer-van Gelder ME; van Agthoven TL; Sarwari R; Sleijfer S; Foekens JA; Dorssers LC
    Endocr Relat Cancer; 2010 Mar; 17(1):215-30. PubMed ID: 19966015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.